Carvedilol plus NUCs for compensated HBV-cirrhosis patients under virological suppression: a randomised, open-label trial.
Bingqiong WangJialing ZhouXiaoning WuYameng SunLei LiPing LiMing-Hui LiWei JiangMingyi XuBo FengXiaoyuan XuJilin ChengWen XieTao HanXiaozhong WangHai LiHongxin PiaoXinyu ZhaoShuyan ChenTongtong MengQiushuang GuanFandong MengYuan Yuan KongXiaojuan OuJi-Dong JiaHong YouPublished in: The American journal of gastroenterology (2023)
The overall results did not show statistically significant differences between the added carvedilol strategy and NUCs monotherapy in preventing EVs progression in virologically suppressed HBV-cirrhosis patients. However, the carvedilol-added approach might offer improved outcomes specifically for patients with medium EVs (NCT03736265).
Keyphrases
- open label
- end stage renal disease
- clinical trial
- ejection fraction
- newly diagnosed
- chronic kidney disease
- hepatitis b virus
- peritoneal dialysis
- study protocol
- prognostic factors
- randomized controlled trial
- phase ii
- hiv infected
- phase iii
- squamous cell carcinoma
- type diabetes
- adipose tissue
- radiation therapy
- liver failure
- weight loss
- hiv infected patients